All items in the Healthy Skepticism Library
All the 20545 items in the Healthy Skepticism Library are listed below in order of publication date with the most recent at the top. There are 100 items per page.
Page 170 of 206 pages ‹ First < 168 169 170 171 172 > Last ›
HSL6802
American Academy of Neurology policy on conflicts of interest: Ethics and Humanities Subcommittee.
Neurology. 1998 Feb;50:(2):332-4
HSL6803
Bernat JL, Goldstein ML, Ringel SP.
Conflicts of interest in neurology.
Neurology 1998 Feb;50:(2):327-31
HSL8188
Reid S.
New ways to take medicine
Pharmaceutical Executive 1998 Feb;18:70-72, 74
HSL13284
Jacoby J, Johar GV, Morrin MÂ.
Consumer Behavior: A Quadrennium
Annual Review of Psychology 1998 Feb;49:319-344
http://www.ovid.com/site/catalog/Journal/273.jsp
HSL2083
McColl A, Smith H, White P, Field J.
General practitioner's perceptions of the route to evidence based medicine: a questionnaire survey.
BMJ 1998 Jan 31;316:(7128):361-5
http://bmj.bmjjournals.com/cgi/content/full/316/7128/361
HSL402
Ioannidis JP.
Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials.
JAMA 1998 Jan 28;279:(4):281-6
http://jama.ama-assn.org/cgi/content/full/279/4/281
HSL19907
Rovner J
Substandard Bosnia drug donations challenged in US Congress
The Lancet 1998 Jan 24;351:275
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2805%2978253-2/fulltext
HSL20519
Sweet M
New fears on doctors' links to drug firms
The Sydney Morning Herald 1998 Jan 233
HSL5331
Evans RS, Pestotnik SL, Classen DC, Clemmer TP, Weaver LK, Orme JF Jr, Lloyd JF, Burke JP.
A computer-assisted management program for antibiotics and other antiinfective agents.
N Engl J Med 1998 Jan 22;338:(4):232-8
http://content.nejm.org/cgi/content/abstract/338/4/232
HSL8220
Clear PR, Grobler M.
Regulating the pharmaceutical industry. Australian scheme has disadvantages.
BMJ 1998 Jan 17;
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2665411
HSL371
Sukkari SR, Sasich LD.
Trials of CCBs.
CMAJ 1998 Jan 13;158:(1):21-3
http://www.cmaj.ca/cgi/reprint/158/1/21
HSL408
Stelfox HT, Chua G, O'Rourke K, Detsky AS.
Conflict of interest in the debate over calcium-channel antagonists.
N Engl J Med 1998 Jan 8;338:(2):101-6
http://content.nejm.org/cgi/content/abstract/338/2/101
HSL19813
Tanouye E
Does Corporate Funding Influence Research?
The Wall Street Journal 1998 Jan 8
HSL20196
TV drug ads creating prescription-pill stampede
San Fransico Chronicle 1998 Jan 7
HSL19954
US Moves to Curb Some Drug Promotions
The New York Times 1998 Jan 6
http://www.nytimes.com/1998/01/06/business/us-moves-to-curb-some-drug-promotions.html
HSL6801
Increased US drug consumption driven by increased spending on direct to the consumer promotion
MaLAM International News 1998 Jan-Feb;16:(1-2):2
HSL8161
Heller A.
New technology advances pharmacy productivity
Drug Store News Chain Pharm 1998 Jan;8:
HSL8162
Frederick J.
Search continues for next generation of drugs
Drug Store News Chain Pharm 1998 Jan;8:
HSL8181
McCarthy R.
Rx ads hit consumer bull's eye
Drug Benefit Trends 1998 Jan;10:23
HSL8198
Craig RP.
Patient as a partner in prescribing: direct to consumer advertising
Journal-of-Managed-Care-Pharmacy 1998 Jan-Feb;4:15-16, 18-19
HSL8225
Nordenberg T.
Direct to you: TV drug ads that make sense.
FDA Consum 1998 Jan-Feb;32:(1):7-10
HSL20317
Heineck I, Gallina SM, da Silva T, Dal Pizzol F, Schenkel EP
Análise da publicidade de medicamentos veiculada em emissoras de rádio do Rio Grande do Sul, Brasil Analysis of non-prescription drug radio advertising in Rio Grande do Sul State, Brazil
Cadernos de Saúde Pública 1998 Jan;
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X1998000100028
HSL20375
Pizzol FD, Silva T, and Schenkel EP
Análise da adequação das propagandas de medicamentos dirigidas à categoria médica distribuídas no Sul do Brasil: Adequacy of drug advertisements distributed to prescribers in Southern Brazil
Cad. Saúde Pública 1998 Jan;14:(1):85-91
http://www.scielo.br/scielo.php?script=sci_abstract&pid=S0102-311X1998000100016&lng=en&nrm=iso&tlng=en
HSL20521
Pines WL
The Challenge of the Internet
Drug Information Journal 1998 Jan;32:(1):277-281
http://dij.sagepub.com/content/32/1/277.abstract
HSL368
Wagner E.
Ghostwriting
The Lancet 1998;351:1741
HSL381
Roughead EE, Gilbert AL, Harvey KJ.
Self-regulatory codes of conduct: are they effective in controlling pharmaceutical representatives' presentations to general medical practitioners?
Int J Health Serv 1998;28:(2):269-79
HSL382
Reeves KN.
Direct-to-consumer broadcast advertising: empowering the consumer or manipulating a vulnerable population?
Food Drug Law J 1998;53:(4):661-79
HSL386
Parker BJ, Delene LM.
Direct-to-consumer prescription drug advertising: content analyis and public policy implications
Journal of Pharmaceutical Marketing & Management 1998;12:(4):27
HSL395
Lexchin J.
Improving the appropriateness of physician prescribing.
Int J Health Serv 1998;28:(2):253-67
HSL1897
Creyer EH, Hrsistodoulakis I.
Marketing pharmaceutical products to physicians. Sales reps influence physicians' impressions of the industry
Mark Health Serv. 1998 Sum;18:(2):34-8
HSL2009
Bourguignon R.
Problems with Prozac
1998
HSL2332
Powers R
Time with drug reps affects prescribing.
1998
HSL3704
Brown P.
Will DTC advertising shape the future of the industry?
Scrip Mag. 1998;3-4
HSL5315
Beck JM, Azari ED.
FDA, off-label use, and informed consent: debunking myths and misconceptions.
Food Drug Law J 1998;53:(1):71-104
HSL5370
Pizor , TC .
A medical publisher reminds us: don't forget the gatekeepers
Med Mark Media 1998;33:65-67
HSL6324
O-Brien KL.
Epidemic of pediatric deaths from acute renal failure caused by diethylene glycol poisoning
JAMA 1998;279:1180
HSL6777
Medicating for a mirage
International Journal of Risk & Safety in Medicine 1998;11:1-3
HSL6778
National survey of consumer reactions to direct-to-consumer advertising
Pennsylvania: Rodale Press 1998
HSL6779
Spotlight: BMS vs CCOHTA
Connection 1998
www.ccohta.ca
HSL6780
Ault A.
US FDA ordered to allow off-label data dissemination
Lancet 1998;352:555
HSL6781
Bauer G.
Pitching drugs to patients
Pharmacy Practice 1998;14:(12):43-44, 46, 48
www.pharmacyconnects.com/pharPrac/index.htm
HSL6782
Baylor-Henry M, Drezin NA.
Regulation of prescription drug promotion: direct-to-consumer advertising.
Clin Ther 1998;20:
HSL6783
Brock TP, Smith MC.
A content analysis of the appeals used in advertising in the Americal Journal of Hospital Pharmacy in 1960, 1970, 1980, and 1990
Journal of Pharmaceutical Marketing & Management 1998;12:(4):43
HSL6784
Center for Drug Evaluation and Research
CDER 1997: report to the nation
: U.S. Department of Health and Human Services 1998
HSL6785
Day M.
He who pays the piper . . .
New Scientist 1998;158:(2133):18-19
HSL6786
Fried S.
Bitter pills: inside the hazardous world of legal drugs
New York: Bantam Books 1998
HSL6788
Gutkin C.
Pharmaceutical industry and the medical profession
Canadian Family Physician 1998;44:1756
HSL6789
Hoey J.
Placing the ads
Canadian Medical Association Journal 1998;159:920
http://www.cma.ca/cmaj/vol-159/issue-8/0920b.htm
HSL6790
Kassirer J.
Cal Ripken, Jr., and prinivil
New England Journal of Medicine 1998;339:2025
HSL6791
Lexchin J.
Placing the ads
Canadian Medical Association Journal 1998;159:920
http://www.cma.ca/cmaj/vol-159/issue-8/0920a.htm
HSL6792
Lexchin J.
The relationship between pharmaceutical regulation and inappropriate prescribing: the case of psychotropic drugs in Canada during the 1960s and early 1970s
International Journal of Risk & Safety in Medicine 1998;11:49-59
HSL6793
Lexchin J, North P.
OMA perspective on comparative advertising of pharmaceutical products
Ontario Medical Review 1998;65:(5):25-27
HSL6794
Mintzes B
Blurring the boundaries: new trends in drug promotion
Amsterdam: Health Action International 1998
www.haiweb.org
HSL6795
Morgan S
Issues for Canadian pharmaceutical policy: Striking a balance: health care systems in Canada and elsewhere
Sainte-Foy, Canada: Sainte-Foy, Canada 1998
HSL6796
Powers RL, Halbritter KA, Arbogast JG, Neely JL, Williams AJ.
Do interactions with pharmaceutical representatives influence antihypertensive medication prescribing practices of family medicine and general internal medicine physicians?
Journal of General Internal Medicine 1998;13:13
HSL6797
Shannon TM.
Trials of CCBs
Canadian Medical Association Journal 1998;158:21-23
http://www.cma.ca/cmaj/vol-158/issue-1/0021b.htm
HSL6799
Sherwood LM.
Cal Ripken, Jr., and prinivil
New England Journal of Medicine 1998;339:2025
HSL6800
Valpy M.
Science friction
Elm Street 1998;26-28, 30, 32, 34-36
HSL6811
McCormack J.
Drug ad hard to swallow
Adbusters 199818-19
www.adbusters.org/adbusters/
HSL8092
Pines WL.
Direct-to-consumer promotion: an industry perspective.
Clin Ther 1998;20:
HSL8093
Maine LL.
Direct-to-consumer advertising: a pharmacy perspective.
Clin Ther 1998;20:
HSL8115
Doucette WR, Schommer JC.
Consumer preferences for drug information after direct-to-consumer advertising
Drug Information Journal 1998;34:(4):1081-1088
HSL8154
McCaffrey DJ, Smith MC, Banahan BF, Frate DA, Gilbert FW.
Continued look into the financial implications of initial noncompliance in community pharmacies: unclaimed prescription audit pilot
Journal of Research in Pharmaceutical Economics 1998;9:(2):33-57
HSL8156
Wechsler J.
Message to marketers: take the high road
Pharmaceutical Executive 1998;1:(2):28-29
HSL8158
Smith D.
It's our health...and we want more than advertising
Pharmaceutical Executive 1998;1:(2):23-24
HSL8159
DTC data
Pharmaceutical Executive 1998;1:(2):33-34
HSL8170
Muse DN.
Medicaid's transition into managed care? Real or imaginary?
Pharmacoeconomics. 1998;14:(Suppl 1):57-67.
http://www.ncbi.nlm.nih.gov/pubmed/10186483
HSL8171
Lasagna L.
Defining our future work.
Pharmacoeconomics 1998;14:
HSL9085
Moynihan R.
Too much medicine? The Business of Health - and Its Risks for You
Sydney: ABC Books 1998
http://www.amazon.com/Too-Much-Medicine-Business-Health/dp/B000OHCGS8/ref=sr_1_4/102-1249992-1219339?ie=UTF8&s=books&qid=1175306755&sr=1-4
HSL9203
Rozek RP.
Critique of the GAO report on differences in prices for prescription drugs between Canada and the United States
Journal of Research in Pharmaceutical Economics 1998 Mar;6:(1):77-91
HSL11547
Miller D.
Mediating Science: promotional strategies, media coverage, public belief and decision making
Scanlon E, Whitelegg E, Yates S. Communicating Science: Contexts and Channels London: Routledge/Open University 1998
http://www.amazon.com/Communicating-Science-Contexts-Channels-University/dp/041519752X/ref=sr_1_14/102-5869202-0212934?ie=UTF8&s=books&qid=1190545477&sr=1-14
HSL13287
Keller KL.
Strategic Brand Management: Building, Measuring, and Managing Brand Equity
New Jersey: Prentice Hall 1998
http://www.pearsonhighered.com/bookseller/academic/product/0,3110,0131888595,00.html
HSL13374
Lapeyre-Mestre M, Desboeuf K, Aptel I, Chale JJ, Montastruc JL.
A comparative survey of antidepressant drug prescribing habits of general practitioners and psychiatrists.
Clin Drug Investig 1998;16:(1):53-61
http://www.ncbi.nlm.nih.gov/pubmed/18370518
HSL18028
Peyrot M, Alperstein NM, Van Doren D, Poli LG
Direct-to-consumer ads can influence behavior. Avertising increases consumer knowledge and prescription drug requests.
Mark Health Serv 1998;18:(2):26-32.
http://www.ncbi.nlm.nih.gov/pubmed/10180332
HSL18353
Glinert LH
Side effect warnings in British medical package inserts: A discourse analytical approach
International Journal of Cognitive Ergonomics 1998;2:(1-2):61-74
HSL20293
Mellers BA, Schwartz A, Cooke AD.
Judgment and decision making.
Annu Rev Psychol 1998;49:447-77:
http://www.annualreviews.org/doi/abs/10.1146/annurev.psych.49.1.447?url_ver=Z39.88-2003&rfr_dat=cr_pub%3Dpubmed&rfr_id=ori%3Arid%3Acrossref.org&journalCode=psych
HSL19869
Misleading promotions in Australia
Scrip 1997 Dec 26;
HSL535
Menkes DB.
Hazardous drugs in developing countries.
BMJ 1997 Dec 13;315:(7122):1557-8
http://bmj.bmjjournals.com/cgi/content/full/315/7122/1557
HSL548
Lewin-Fetter V.
Pharmaceutical representatives.
Lancet 1997 Dec 13;350:(9093):1784
HSL19930
Leighton G, Telford ME
Evidence based advertising?: Reply from manufactuter
BMJ 1997 Dec 13;315:1621
HSL19931
Hamet P
Reply from author of STONE study
BMJ 1997 Dec 13;315:1621-1622
HSL19932
Mindell J, Kemp T
Evidence based advertising? Only two fifths of advertisements cited published, peer reviewed references.
BMJ 1997 Dec 13;315:1622
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2127972/
HSL19933
Crane S
Evidence based advertising? 'Cash for questions' is not limited to MPs.
BMJ 1997 Dec 13;315:1622
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2127977/
HSL19934
Smart S, Williams C
Half of drug advertisements in BMJ over six months cited no supporting evidence
BMJ 1997 Dec 13;315:1622-3
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2127981/
HSL19935
Greenhalgh T.
Advertisements for donepezil. More convincing evidence of efficacy needs to be cited.
BMJ 1997 Dec 13;315:1623
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2127985/
HSL19936
Stein K, Milne R, Best L
Advertisements for donepezil. BMJ should require advertisements to detail actual state of evidence.
BMJ 1997 Dec 13;315:1623
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2127989/
HSL19937
Wilkinson D
Advertisements for donepezil. Review of drug in Drug and Therapeutics Bulletin is uninformed
BMJ 1997 Dec 13;315:1625
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2127997/
HSL19964
Hamet P
Evidence based advertising?: Reply from author of STONE study
BMJ 1997 Dec 13;315:1622
http://www.jstor.org/discover/10.2307/25176531?uid=3737536&uid=2129&uid=2134&uid=2&uid=70&uid=4&sid=55871785133
HSL19965
Boothby H, Zaidi SMN, Seth V, Khalaf S, Jameel H, Mahomed S, Al-Yassiri
Advertisements for donepezil: National policy to be set for prescribing of this drug
BMJ 1997 Dec 13;315:1624
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2127992/
HSL19966
Hooper P, Whitehead AM
Advertisements for donepezil: Drug company's reply
BMJ 1997 Dec 13;315:1624
http://www.jstor.org/discover/10.2307/25176532?uid=3737536&uid=2129&uid=2134&uid=2&uid=70&uid=4&sid=55871785133
HSL19967
Jones RW, Mann JB, Saunders SA
Advertisements for donepezil. Prices charged for private prescriptions for donepezil show huge variation.
BMJ 1997 Dec 13;315:(7122):1624
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2127995/
HSL18031
Greenhalgh T, Gill P.
Pressure to prescribe.
BMJ 1997 Dec 6;315:(7121):1482-3
http://www.bmj.com/cgi/content/extract/315/7121/1482
HSL18032
Britten N, Ukoumunne O.
The influence of patients' hopes of receiving a prescription on doctors' perceptions and the decision to prescribe: a questionnaire survey.
BMJ 1997 Dec 6;315:(7121):1506-10
http://www.bmj.com/cgi/content/full/315/7121/1506?view=long&pmid=9420493
HSL1550
Mansfield PR.
MaLAM, a medical lobby for appropriate marketing of pharmaceuticals.
Med J Aust 1997 Dec 1-15;167:(11-12):590-2
http://www.mja.com.au/public/issues/xmas/mansfield/mansfield.html
HSL8228
Americans at risk from self-medication, survey reveals
American Journal of Health System Pharmacy 1997 Dec 1;54:2664, 2666
HSL544
Lipsky MS, Taylor CA.
The opinions and experiences of family physicians regarding direct-to-consumer advertising.
J Fam Pract 1997 Dec;45:(6):495-9
HSL6776
Mansfield P, Vitry A.
Re: the promotion of prescription products in Australia
1997 Dec;
HSL8176
Tanouye E, Langreth R.
U.S. drug patents
Eastern Pharmacist 1997 Dec;40:21-24
HSL8182
Reissman D.
Who's taking the risk for prescription drug costs?
Drug Benefit Trends 1997 Dec;9:19
HSL8185
Wechsler J.
Direct-to-marketers: FDA talks to the industry
Pharmaceutical Executive 1997 Dec;17:52-54, 56, 58, 60, 62
Page 170 of 206 pages ‹ First < 168 169 170 171 172 > Last ›
